The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC
- 14 August 2009
- journal article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 28 (S1), S1-S3
- https://doi.org/10.1038/onc.2009.195
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trialThe Lancet, 2009
- Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancerCancer, 2008
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2006
- Unraveling the Mystery of Prognostic and Predictive Factors in Epidermal Growth Factor Receptor TherapyJournal of Clinical Oncology, 2006
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2005
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung CancerJAMA, 2003
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Lung Cancer — Time to Move on from ChemotherapyThe New England Journal of Medicine, 2002